百济神州2024年业绩快报：归母净利润亏损49.78亿元
2月27日，百济神州（688235/06160/BGNE）发布公告，2024年度主要财务数据为初步核算数据，未经审计。报告期内，公司营业总收入为272.14亿元，较上年同期增长56.2%，其中产品收入为269.94亿元，同比上升74.1%。归母净利润约亏损49.78亿元，相较上年同期的亏损67.2亿元有所改善。
报告期末，公司总资产为428.35亿元，较期初增加4.2%；归属于母公司的所有者权益为241.75亿元，较期初减少3.7%。产品收入的增长主要得益于百悦泽®（泽布替尼胶囊）和百泽安®（替雷利珠单抗）的销售提升，其中百悦泽®全球销售额达188.59亿元，同比增长106.4%。公司在中国BTK抑制剂市场的市场份额持续保持领先地位。
2024年前三季度，百济神州实现收入191.36亿元，归母净利润-36.87亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10